Table 3.
Baseline characteristics of participants in the included trials
| Trial | Country | Centers | Patients | Sample size | Male % | Mean age Y | Diabetes% | Treatment duration M | Lost to follow-up % | Blinding | ITT analysis |
| CHANCE 2013 | China | 114 | Minor ischemic stroke or high-risk TIA | 5170 | 66 | 63 | 21 | 3 | 0.7 | Double-blind | Yes |
| CHARI-SM 2006 | Worldwide | 768 | CVD or multiple risk factors | 15603 | 70 | 64 | 42 | 28 | 0.5 | Double-blind | Yes |
| CREDO 2002 | United States and Canada | 99 | Those would undergo elective PCI | 2116 | 71 | 62 | 26 | 12 | 1.1 | Double-blind | Yes |
| CURE 2001 | Worldwide | 482 | ACS without ST-segment elevation | 12562 | 62 | 64 | 23 | 12 | 0.1 | Double-blind | Yes |
| POINT 2018 | Worldwide | 269 | Acute ischemic stroke or high-risk TIA | 4881 | 55 | 65 | 27 | 3 | 4.1 | Double-blind | Yes |
| SPS3 2012 | Worldwide | 82 | Recent symptomatic lacunar infarcts | 3020 | 63 | 63 | 36 | 41 | 2.0 | Double-blind | Yes |
ITT: Intention-to-treat; TIA: Transient ischemic attack; CVD: Cardiovascular disease; PCI: Percutaneous coronary intervention; ACS: Acute coronary syndromes.